SCHEMBL2032060

SCHEMBL2032060

Cn1ccc2cccc(N)c2c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.44
RPS6KA3 P51812 1/20 0.44
MELK Q14680 1/20 0.44
STK24 Q9Y6E0 1/20 0.44
KMT2A Q03164 7/20 0.41
ALDH1A1 P00352 7/20 0.41
MEN1 O00255 6/20 0.41
KDM4E B2RXH2 5/20 0.41
MAPT P10636 5/20 0.41
GAA P10253 4/20 0.41
HTT P42858 2/20 0.41
THRB P10828 1/20 0.41
RECQL P46063 1/20 0.41
BRD9 Q9H8M2 2/20 0.41
BRD4 O60885 1/20 0.41
TAF1 P21675 1/20 0.41
BRPF1 P55201 1/20 0.41
CREBBP Q92793 1/20 0.41
CECR2 Q9BXF3 1/20 0.41
TYMS P04818 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3576881 0.98 JAK2 (0.43) JAK2RPS6KA3MELKSTK24KMT2A
SCHEMBL10005837 0.79 BRD4 (0.42) KMT2AALDH1A1MEN1KDM4EGAA
SCHEMBL3577290 0.78 TAF1 (0.41) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL13061910 0.78 BRD9 (0.41) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL31743137 0.78 MAPT (0.42) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL31364684 0.78 BRD9 (0.41) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL26597056 0.77 JAK2 (0.41) JAK2RPS6KA3MELKSTK24KMT2A
SCHEMBL27191760 0.75 BRD9 (0.39) ALDH1A1KDM4EBRD9BRD4TAF1
SCHEMBL26634448 0.75 JAK2 (0.39) JAK2RPS6KA3MELKSTK24KMT2A
SCHEMBL30847966 0.72 PRKCI (0.39) ALDH1A1MAPTPRKCIHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100081650-A1 Antimicrobial Compounds AXTEN JEFFREY MICHAEL 2010-04-01 US claimed
EP-1537123-B1 AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS GLAXO GROUP LTD (GB) 2009-04-29 EP claimed
US-20060189604-A1 Compounds GLAXO GROUP LIMITED (GB) 2006-08-24 US claimed
EP-4272832-A2 ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF Lakewood Amedex, Inc. (US) 2023-11-08 EP disclosed
US-11795192-B2 Antimicrobial compounds, compositions, and uses thereof Lakewood Amedex, Inc. (US) 2023-10-24 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109120-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023108536-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
US-20210139522-A1 ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF Lakewood Amedex, Inc. 2021-05-13 US disclosed
US-9096624-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2015-08-04 US disclosed
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2013-09-05 US disclosed
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 US disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 US disclosed
US-20100081650-A1 Antimicrobial Compounds AXTEN JEFFREY MICHAEL 2010-04-01 US disclosed
US-7622481-B2 Antibacterial compounds GLAXO GROUP LIMITED (GB) 2009-11-24 US disclosed
EP-1537123-B1 AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS GLAXO GROUP LTD (GB) 2009-04-29 EP disclosed
US-20060189604-A1 Compounds GLAXO GROUP LIMITED (GB) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139522-A1 ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF CFTR, ABCB11, CEL JAK2 781/4885RPS6KA3 2185/4885MELK 3270/4885
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS JAK2 15/4885RPS6KA3 203/4885MELK 613/4885
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS JAK2 15/4885RPS6KA3 203/4885MELK 613/4885
US-20060189604-A1 Compounds ELANE, PIGS, SDHA JAK2 3578/4885RPS6KA3 2010/4885MELK 3275/4885
US-11795192-B2 Antimicrobial compounds, compositions, and uses thereof CAT, MPO, NISCH JAK2 3298/4885RPS6KA3 873/4885MELK 2156/4885
US-20100081650-A1 Antimicrobial Compounds ELANE, NISCH, PIGS JAK2 4631/4885RPS6KA3 1297/4885MELK 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.